S-095029
- Generic Name
- S-095029
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: S095024 RDEDrug: S095029 RDEDrug: S095018 Recommended Dose Expansion (RDE)
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 176
- Registration Number
- NCT06162572
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸University of Kansas Medical Center, Lawrence, Kansas, United States
🇺🇸Henry Ford Health, Detroit, Michigan, United States
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Phase 1
Recruiting
- Conditions
- MSI-H/dMMR Gastroesophageal-junction CancerMSI-H/dMMR Gastric Cancer
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06116136
- Locations
- 🇮🇹
A.O.U. Seconda Università Degli Studi Di Napoli, Campania, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumor, Milan, Italy
🇮🇹A.O.U. Pisana-Ospedale Santa Chiara, Pisa, Italy
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 51
- Registration Number
- NCT05162755
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath